longbridgelongbridge
  • Platform Features
    Features
    Investment ProductsPrivate Wealth ManagementTrading ToolsMarket Data ServicesAnalysis ToolsNews ServicesFor Developers
    Account Types
    For IndividualsFor Institutions
  • Café
longbridge
© 2026 Longbridge|Terms of ServicePrivacy Policy

Baxter

BAX

----
Start trading
OverviewOverviewNewsNewsPostsPostsFinancialsFinancialsForecastForecastValuationValuationShareholdersShareholdersProfileProfile
LongbridgeAI

Current ValuationThe current P/E ratio is -11.09, within the reasonable range, cheaper than 73.31% of the time in the past 5 years, and the industry ranks 134/175, the industry Median -0.90.

-11.09xP/E
$22.80Stock price
$-2.06Earnings per share
-11.09xP/E
Stock price$22.80Earnings per share$-2.06

Historical Valuation

P/E ratioTypical rangeMedian
P/E ratio
-7.20x
Typical range
-13.16x–31.99x

Peer P/E ratio Comparison

It displays how the company's P/E ratio compares to top companies within its industry.
012243648

The industry median valuation is currently at or below 0 and may not serve as a meaningful benchmark.

Industry P/E ratio Comparison

This shows the distribution of companies by P/E ratio range and their projected earnings per share growth for the next fiscal year.
0x30x60x90x120x150x
P/E ratio
Name/Symbol
BAXUSBaxter
-11.09x141.71%$11.79B
GKOSUSGlaukos
-51.38x75.34%$9.66B
TFXUSTeleflex
-5.11x118.39%$5.28B
PLSEUSPulse Biosciences
-47.99x27.55%$3.84B
IRTCUSIRhythm
-258.40x71.96%$3.60B
AXGNUSAxogen
-77.35x31.25%$2.60B
BFLYUSButterfly Network
-28.03x34.41%$2.10B
ASSTUSStrive
-2.13x63.26%$2.08B
NVCRUSNovocure
-13.08x2.52%$1.94B
ATECUSAlphatec
-14.29x41.67%$1.57B
KMTSUSKestra Medical Tech
-9.55x0.94%$1.43B
DRTSUSAlpha Tau Medical
-15.20x--$1.41B
IARTUSIntegra LifeSciences
-163.56x109.50%$1.18B
TNDMUSTandem Diabetes
-18.54x77.82%$1.17B
AORTUSArtivion
-356.77x266.67%$1.14B
PRCTUSPROCEPT BioRobotics
-10.07x3.47%$1.11B
ENOVUSEnovis
-0.94x100.97%$1.04B
BBNXUSBeta Bionics
-13.50x15.43%$984.82M
CBLLUSCeribell
-14.17x35.15%$935.27M
SIBNUSSI-BONE
-55.41x8.85%$810.77M

Risk Warning

Timeframes using financial data from S&P Global. The feature provides key metrics such as price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S) ratios, and dividend yield. For reference only and does not constitute investment advice.